Cargando…
Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936511/ https://www.ncbi.nlm.nih.gov/pubmed/27389496 http://dx.doi.org/10.1038/srep28124 |
| _version_ | 1782441573685919744 |
|---|---|
| author | Gallo, Linda A. Ward, Micheal S. Fotheringham, Amelia K. Zhuang, Aowen Borg, Danielle J. Flemming, Nicole B. Harvie, Ben M. Kinneally, Toni L. Yeh, Shang-Ming McCarthy, Domenica A. Koepsell, Hermann Vallon, Volker Pollock, Carol Panchapakesan, Usha Forbes, Josephine M. |
| author_facet | Gallo, Linda A. Ward, Micheal S. Fotheringham, Amelia K. Zhuang, Aowen Borg, Danielle J. Flemming, Nicole B. Harvie, Ben M. Kinneally, Toni L. Yeh, Shang-Ming McCarthy, Domenica A. Koepsell, Hermann Vallon, Volker Pollock, Carol Panchapakesan, Usha Forbes, Josephine M. |
| author_sort | Gallo, Linda A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4936511 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49365112016-07-13 Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice Gallo, Linda A. Ward, Micheal S. Fotheringham, Amelia K. Zhuang, Aowen Borg, Danielle J. Flemming, Nicole B. Harvie, Ben M. Kinneally, Toni L. Yeh, Shang-Ming McCarthy, Domenica A. Koepsell, Hermann Vallon, Volker Pollock, Carol Panchapakesan, Usha Forbes, Josephine M. Sci Rep Erratum Nature Publishing Group 2016-07-07 /pmc/articles/PMC4936511/ /pubmed/27389496 http://dx.doi.org/10.1038/srep28124 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Erratum Gallo, Linda A. Ward, Micheal S. Fotheringham, Amelia K. Zhuang, Aowen Borg, Danielle J. Flemming, Nicole B. Harvie, Ben M. Kinneally, Toni L. Yeh, Shang-Ming McCarthy, Domenica A. Koepsell, Hermann Vallon, Volker Pollock, Carol Panchapakesan, Usha Forbes, Josephine M. Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| title | Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| title_full | Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| title_fullStr | Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| title_full_unstemmed | Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| title_short | Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| title_sort | erratum: once daily administration of the sglt2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936511/ https://www.ncbi.nlm.nih.gov/pubmed/27389496 http://dx.doi.org/10.1038/srep28124 |
| work_keys_str_mv | AT gallolindaa erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT wardmicheals erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT fotheringhamameliak erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT zhuangaowen erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT borgdaniellej erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT flemmingnicoleb erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT harviebenm erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT kinneallytonil erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT yehshangming erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT mccarthydomenicaa erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT koepsellhermann erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT vallonvolker erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT pollockcarol erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT panchapakesanusha erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice AT forbesjosephinem erratumoncedailyadministrationofthesglt2inhibitorempagliflozinattenuatesmarkersofrenalfibrosiswithoutimprovingalbuminuriaindiabeticdbdbmice |